Overview

• Eye health company's Q4 revenue grew 10%, beating analyst expectations

• Adjusted EBITDA for Q4 beat analyst expectations

• Adjusted net income for Q4 missed analyst expectations

Outlook

• Bausch + Lomb sees 2026 revenue between $5.375 bln and $5.475 bln

• Company expects 2026 adjusted EBITDA of $1.000 bln to $1.050 bln

• Foreign exchange tailwinds expected to contribute $30 mln to 2026 revenue

Result Drivers

• VISION CARE GROWTH - Growth in Vision Care segment was driven by increased demand for contact lenses and consumer products like LUMIFY and dry eye products

• PHARMACEUTICALS GROWTH - Pharmaceuticals segment growth was driven by increased sales of MIEBO and international pharmaceuticals

• SURGICAL SEGMENT - Surgical segment growth was driven by demand for premium IOLs and increased equipment sales, partially offset by a voluntary recall of certain enVista IOL products

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Bausch + Lomb Corp is $17.00, about 4.1% below its February 17 closing price of $17.73

• The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBw61NTqa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)